Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Liminal BioSciences stock
Learn how to easily invest in Liminal BioSciences stock.
Liminal BioSciences Inc is a biotechnology business based in the US. Liminal BioSciences shares (LMNL) are listed on the NASDAQ and all prices are listed in US Dollars. Liminal BioSciences employs 251 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Liminal BioSciences
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – LMNL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Liminal BioSciences stock price (NASDAQ: LMNL)Use our graph to track the performance of LMNL stocks over time.
Liminal BioSciences shares at a glance
|Latest market close||$1.10|
|52-week range||$0.88 - $6.95|
|50-day moving average||$1.27|
|200-day moving average||$2.87|
|Wall St. target price||$3.63|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.27|
Buy Liminal BioSciences shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Liminal BioSciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Liminal BioSciences price performance over time
|1 week (2022-01-10)||5.77%|
|1 month (2021-12-17)||4.76%|
|3 months (2021-10-15)||-43.88%|
|6 months (2021-07-16)||-68.21%|
|1 year (2021-01-15)||-79.89%|
|2 years (2020-01-17)||-90.04%|
|3 years (2019-01-17)||391.51%|
|5 years (2017-01-17)||1.6463|
Liminal BioSciences financials
|Revenue TTM||$3.3 million|
|Gross profit TTM||$-55,542,000|
|Return on assets TTM||-45.53%|
|Return on equity TTM||-321.66%|
|Market capitalisation||$32.3 million|
TTM: trailing 12 months
Liminal BioSciences share dividends
We're not expecting Liminal BioSciences to pay a dividend over the next 12 months.
Have Liminal BioSciences's shares ever split?
Liminal BioSciences's shares were split on a 1:1000 basis on 4 July 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Liminal BioSciences shares – just the quantity. However, indirectly, the new 99900% higher share price could have impacted the market appetite for Liminal BioSciences shares which in turn could have impacted Liminal BioSciences's share price.
Liminal BioSciences share price volatility
Over the last 12 months, Liminal BioSciences's shares have ranged in value from as little as $0.88 up to $6.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Liminal BioSciences's is 1.4895. This would suggest that Liminal BioSciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Liminal BioSciences overview
Liminal BioSciences Inc. , a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma-Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050), which is in Phase 1 for the treatment of idiopathic pulmonary fibrosis and respiratory diseases. The Plasma-Derived Therapeutics segment focused on the development of its plasma-derived product candidate Ryplazim, a purified glu-plasminogen derived from human plasma that acts as a plasminogen replacement therapy for patients deficient in plasminogen protein. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc.
Liminal BioSciences in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Joe Manchin's former aides gain influential lobbying clients as their ex-boss battles Biden's agenda
Frequently asked questionsWhat percentage of Liminal BioSciences is owned by insiders or institutions?
Currently 64.054% of Liminal BioSciences shares are held by insiders and 0.505% by institutions. How many people work for Liminal BioSciences?
Latest data suggests 251 work at Liminal BioSciences. When does the fiscal year end for Liminal BioSciences?
Liminal BioSciences's fiscal year ends in December. Where is Liminal BioSciences based?
Liminal BioSciences's address is: 440 Boulevard Armand-Frappier, Laval, QC, Canada, H7V 4B4 What is Liminal BioSciences's ISIN number?
Liminal BioSciences's international securities identification number is: CA53272L1031 What is Liminal BioSciences's CUSIP number?
Liminal BioSciences's Committee on Uniform Securities Identification Procedures number is: 53272L103
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Ask an Expert